OMNIPAQUE 9 (iohexol)
Omnipaque (iohexol) is a non-ionic, water-soluble radiographic contrast agent indicated for a wide range of diagnostic imaging procedures in adult and pediatric patients (including infants aged 2 weeks and older for specific applications). It is FDA-approved for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity administration. Key clinical applications include myelography, CT cisternography, cardiac ventriculography, angiography (cerebral, peripheral, and pulmonary), excretory urography, and visualization of the gastrointestinal tract and joint spaces.
How OMNIPAQUE 9 Works
The iodine atoms in iohexol attenuate X-ray radiation in direct proportion to the drug's concentration in the body. Because this concentration changes over time through distribution and excretion, iohexol provides time-dependent image contrast, allowing for the clear visualization of specific vascular, neurological, and visceral structures.
Details
- Status
- Prescription
- First Approved
- 1985-12-26
- Routes
- ORAL
- Dosage Forms
- SOLUTION
OMNIPAQUE 9 Approval History
What OMNIPAQUE 9 Treats
10 indicationsOMNIPAQUE 9 is approved for 10 conditions since its original approval in 1985. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Myelography and CT myelography
- CT cisternography
- Cardiac ventriculography
- Aortography
- Coronary arteriography
- Cerebral arteriography
- Peripheral arteriography
- Intra-arterial digital subtraction angiography (IA-DSA)
OMNIPAQUE 9 Boxed Warning
RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyp...
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions (5.1) ]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 and 350 mg IODINE/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures. Intrathecal administration of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema. ( 2.2 , 2.8 , 5.1 )
OMNIPAQUE 9 Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to OMNIPAQUE 9
3 of 6FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
GE HEALTHCARE's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
21 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06709521 | 23-0013 5UM1AI104681-12 | Ph 4 | recruiting | Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) |
| NCT03997370 | NRG-GY022 NCI-2019-04008, NRG-GY022 | Ph 1 | active not recruiting | Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol |
| NCT04649229 | 2000028712 | Ph 4 | completed | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 |
| NCT02050269 IoxRea | PHAO13-SE / IoxRea 2013-003936-65, 2013-R49 | Ph 3 | completed | Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study |
| NCT04113109 | #191228 | Ph 4 | completed | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 |
| NCT05105009 | 19-1131 | Ph 1 | completed | Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function |
| NCT02772276 results posted | ORFM-2 | Ph 2 | completed | Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types |
| NCT05615467 | 18629 J2P-MC-LXBE | Ph 1 | completed | A Study of Effect of LY3556050 on Metformin in Healthy Participants |
| NCT05580250 | 18353 J2D-JE-CVAD | Ph 1 | withdrawn | A Study of LY3526318 in Healthy Male Japanese Participants |
| NCT03631771 | GE-012-103/19476/OPY-44-002 | Ph 4 | withdrawn | Pediatric Risk of Hypothyroidism With Iodinated Contrast Media |
| NCT04627831 | CE-Iohexol - Study 201 Ligand 201, CAP201 | Ph 2 | withdrawn | Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography |
| NCT04742816 | CCTG 605s | Ph 4 | completed | Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients |
| NCT01839526 | AGAL19110 2012-001966-14, MSC 12711 | Ph 1 | terminated | A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease |
| NCT04156750 | 17612 J2P-MC-LXBA | Ph 1 | completed | A Study of LY3556050 in Healthy Participants |
| NCT03826602 | SGNTUC-020 | Ph 1 | completed | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin |
| NCT03415997 | NSHA REB 1023119 | Ph 4 | completed | Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight |
| NCT02884089 results posted | 16536 I3Y-MC-JPCK | Ph 1 | completed | A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants |
| NCT03545087 | 16007 I8D-MC-AZEN | Ph 1 | withdrawn | A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants |
| NCT02246998 results posted | GS-US-236-0140 2014-002095-93 | Ph 4 | completed | Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults |
| NCT02522338 HIVOL | 1008078 2010-022272-31 | Ph 4 | completed | Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance |
| NCT07643467 FLARE | 105008 | Ph 4 | not yet recruiting | Fluorescent Probe for Assessment of Renal Elimination |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OMNIPAQUE 9 FDA Label Details
Indications & Usage
FDA Label (PDF)OMNIPAQUE 9 is indicated for the treatment of Myelography and CT myelography; CT cisternography; Cardiac ventriculography; Aortography; Coronary arteriography; Cerebral arteriography; Peripheral arteriography; Intra-arterial digital subtraction angiography (IA-DSA); Pulmonary angiography; Excretory urography.
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNI...
Track OMNIPAQUE 9 with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.